Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Taysha Gene Therapies Inc shares valued at $2,062,500 were purchased by Manning Paul B on May 30 ’25. At $2.75 per share, Manning Paul B acquired 750,000 shares. The insider’s holdings grew to 2,841,704 shares worth approximately $7.79 million following the completion of this transaction.
As published in their initiating research note from BofA Securities on July 11, 2025, Taysha Gene Therapies Inc [TSHA] has been a Buy and the price target has been revised to $8. Analysts at BMO Capital Markets started covering the stock with ‘”an Outperform”‘ outlook in a report released in late June. As of April 09, 2024, Piper Sandler has initiated its “an Overweight” rating for TSHA. Earlier on February 01, 2023, Jefferies downgraded its rating. Their new recommendation was “a Hold” for TSHA stock which previously was a “a Buy”.
Analyzing TSHA Stock Performance
On last trading session,, Taysha Gene Therapies Inc [NASDAQ: TSHA] rose 4.58% to $2.74. The stock’s lowest price that day was $2.67, but it reached a high of $2.9089 in the same session. During the last five days, there has been a surge of approximately 1.86%. Over the course of the year, Taysha Gene Therapies Inc shares have jumped approximately 19.13%.
Support And Resistance Levels for Taysha Gene Therapies Inc (TSHA)
RSI (Relative Strength Index) is 59.76 on the 14-day chart, showing neutral technical sentiment.
Is Taysha Gene Therapies Inc subject to short interest?
Stocks of Taysha Gene Therapies Inc saw a sharp rise in short interest on 2025-07-15 jumping by 10.69 million shares to 43.96 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 33.27 million shares. A jump of 24.31% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 15.25 of the overall float, the days-to-cover ratio (short ratio) jumped to 15.25.
Which companies own the most shares of Taysha Gene Therapies Inc (TSHA)?
In terms of Taysha Gene Therapies Inc share price expectations, FactSet research, analysts set an average price target of 8.5 in the next 12 months, up nearly 224.43% from the previous closing price of $2.62. Analysts anticipate Taysha Gene Therapies Inc stock to reach 44 by 2025, with the lowest price target being 5. In spite of this, 8 analysts ranked Taysha Gene Therapies Inc stock as Buy at the end of 2025. On January 27, 2023, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $3.
